Tag Archives: drug pricing

Drug Pricing and Payment Policy: Key 2018 Developments and Potential 2019 Changes and Challenges

Following a number of drug pricing reforms implemented or proposed in 2018, 2019 likely will bring more action from HHS and Congress to reduce drug prices. Key Points: In 2018, the Administration implemented and proposed several policy changes to reduce drug prices or spending, and Congress passed new legislation prohibiting health plans from preventing pharmacies from informing plan… Read More »

Trump Administration Proposes Requiring Disclosure of Drug Prices in TV Ads

The Trump Administration is moving full speed ahead with its proposals under the Blueprint to Lower Drug Prices (the “Blueprint”).  Earlier this week, the Centers for Medicare & Medicaid Services (“CMS”) released a proposed rule that would require pharmaceutical manufacturers to disclose the list price of their pharmaceutical products in direct-to-consumer (“DTC”) television ads (the “Proposed Rule”).  This comes only a week… Read More »

August 2018: Where Are We Now With 340B?

By | August 1, 2018

It seems like every week, there are multiple new developments in the 340B Drug Discount Program. In just the last few weeks, we have seen a new Senate hearing, a new GAO Report, a new House hearing, and introduction of more than a dozen new bills in Congress that would impact 340B. To understand where things may be… Read More »

CMS Focuses on a Modern Medicare in New Proposed Rules

Earlier this month, CMS proposed changes to the Medicare Physician Fee Schedule (the “PFS Proposed Rule“) and Quality Payment Program (the “QPP Proposed Rule“) with the goal of “modernizing Medicare and restoring the doctor-patient relationship.” The proposed changes achieve this goal by streamlining the billing process and reducing the amount of paperwork providers face, empowering providers to maximize use of electronic health record systems, and… Read More »